60 DEGREES PHARMACEUTICALS, INC. financial statements
Income statement, balance sheet and cash flow statement for the last 4 fiscal years, taken from the XBRL data 60 DEGREES PHARMACEUTICALS, INC. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2023
FY2023
FY2024
FY2025
Revenue
0.22
0.25
0.61
1.01
Cost of revenue
0.43
0.47
0.38
0.78
Gross profit
-0.21
-0.22
0.22
0.22
Research and development
0.53
0.69
4.99
2.11
General and administrative
1.3
4.24
5.03
6.28
Operating expenses
1.83
4.93
10
8.39
Operating income
-1.75
-5.15
-9.72
-7.76
Interest expense
3.99
2.29
0.01
0.01
Other non-operating income
-0.04
-0.08
1.76
0.39
Pre-tax income
-6.18
-3.81
-7.96
-7.37
Income tax
0
0
0
0
Income from continuing operations
0.08
-0.22
Net income to minority interests
0
-0.05
-0.01
-0
Net income
-6.18
-3.77
-7.95
-7.37
EBITDA
-1.72
-5.13
-9.7
-7.72
EPS, basic
-623.83
-236.62
-74.17
-11.73
EPS, diluted
-623.83
-236.62
-74.17
-11.73
Shares, basic (weighted)
0.01
0.02
0.11
0.67
Shares, diluted (weighted)
0.01
0.02
0.11
0.67
Balance sheet
FY2023
FY2023
FY2024
FY2025
Cash and equivalents
0.26
2.14
1.66
1.51
Short-term investments
1.73
1.24
Receivables
0.05
0.23
0.49
0.51
Inventory
0.52
0.47
0.44
0.66
Other current assets
0
4.4
1.07
0.98
Total current assets
1.1
7.24
5.39
4.9
Property, plant and equipment
0.02
0.06
0.15
0.25
Lease right-of-use assets
0.01
0.01
Intangible assets
0.16
0.23
0.16
0.22
Other non-current assets
0.48
0.22
0.22
Total assets
1.3
7.78
5.76
5.37
Accounts payable
0.76
0.51
1.01
1.46
Accrued liabilities
0.02
Short-term debt
0.01
0.01
0.01
Total current liabilities
23.9
2.84
1.66
1.84
Long-term debt
16.9
0.15
0.14
Total liabilities
25.4
2.99
1.8
1.99
Total debt
16.9
0.15
0.15
0.15
Paid-in capital
5.16
27.5
34.9
41.6
Retained earnings
-28.8
-32.6
-40.5
-47.9
Other comprehensive income
0.07
0.14
0.14
0.14
Shareholders' equity
-23.6
4.87
4.04
3.46
Minority interests
-0.57
-0.07
-0.08
-0.08
Total equity
-24.1
4.8
3.96
3.38
Total liabilities and equity
1.3
7.78
5.76
5.37
Shares outstanding
0.02
0.14
1.16
Cash flow statement
FY2023
FY2023
FY2024
FY2025
Net income
-6.18
-3.81
-7.96
-7.37
Depreciation and amortization
0.03
0.02
0.01
0.04
Stock-based compensation
0
0.21
3.61
0.46
Deferred income tax
0
0
Change in receivables
0.1
-0.19
-0.26
-0.02
Change in inventory
0.01
0.21
0.02
-0.47
Change in payables
0.17
-0.21
0.5
0.49
Cash from operations
-1.01
-4.54
-5.65
-6.85
Capital expenditures
-0.06
-0.1
-0.14
Purchases of investments
-1.71
-1.24
Cash from investing
-0.06
-0.12
-1.89
0.25
Stock issued
1.05
1.05
Cash from financing
1.22
6.47
7.05
6.44
Exchange rate effect
0.06
0
0.01
Net change in cash
0.15
1.88
-0.48
-0.15
Free cash flow
-4.6
-5.75
-6.99
Interest paid
0
0.18
0.01
0.01
Income taxes paid
0
0
0
0
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $0.52 on November 10, 2026.
Profitability
Metric
Value
How it is calculated
Gross margin
19.4%
Gross profit / revenue.
Operating margin
-774.8%
Operating income / revenue.
EBITDA margin
-769.3%
EBITDA (operating income + depreciation and amortization) / revenue.
Pre-tax margin
-730.3%
Pre-tax income / revenue.
Net margin
-729.9%
Net income / revenue.
FCF margin
-800.6%
Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin
-789.8%
Cash from operations / revenue.
Return on equity (ROE)
-310.2%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-189.3%
Net income / average total assets.
Return on invested capital (ROIC)
-390.4%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
R&D / revenue
209.6%
Research and development expense / revenue.
Stock-based pay / revenue
37.2%
Stock-based compensation (from the cash flow statement) / revenue.
Capex / revenue
10.8%
Capital expenditures / revenue.
D&A / revenue
5.5%
Depreciation and amortization / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
65.5%
Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y
65.2%
Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Gross profit growth, 1y
0.4%
Gross profit vs the same period a year earlier. Only from a positive base.
Book value growth, 1y
-14.2%
Book value vs the same period a year earlier. Only from a positive base.
Total assets growth, 1y
-6.8%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
60.5%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Share count change, 1y
489.6%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
307.5%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
2.32x
Current assets / current liabilities.
Quick ratio
0.99x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
0.64x
(Cash + short-term investments) / current liabilities.
Debt / equity
0.06x
Total debt / shareholders' equity. Not shown when equity is negative.
Debt / assets
3.5%
Total debt / total assets.
Liabilities / assets
41.0%
Total liabilities / total assets.
Net debt
-$872.6K
Total debt - cash - short-term investments. Negative means more cash than debt.
Days inventory + days sales outstanding - days payables.
Per share
Metric
Value
How it is calculated
EPS, diluted
-$3.06
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share
$0.42
Revenue / diluted weighted shares.
FCF per share
-$3.35
Free cash flow / diluted weighted shares.
Operating cash flow per share
-$3.31
Cash from operations / diluted weighted shares.
Book value per share
$0.98
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/S
1.65x
Market cap / revenue.
P/B
0.70x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
0.79x
Market cap / tangible book value, when positive.
EV/Sales
0.86x
Enterprise value / revenue.
FCF yield
-485.9%
Free cash flow / market cap.
Earnings yield
-443.0%
Net income / market cap (the inverse of P/E).
What was 60 DEGREES PHARMACEUTICALS, INC.'s revenue in fiscal 2025?
60 DEGREES PHARMACEUTICALS, INC. reported revenue of $1.0M for fiscal 2025, 65.5% higher than the year before.
Was 60 DEGREES PHARMACEUTICALS, INC. profitable in fiscal 2025?
No. It reported a net loss of $7.4M.
How much free cash flow did 60 DEGREES PHARMACEUTICALS, INC. generate in fiscal 2025?
Cash from operations of $6.8M minus capital expenditures of $139.9K left free cash flow of -$7.0M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.